1 Guidance

1 Guidance

This guidance replaces Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment‑induced anaemia (NICE technology appraisal guidance 142, issued in May 2008).

The review of epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment‑induced anaemia has resulted in a change in the guidance. See About this guidance for more information.

1.1 Erythropoiesis‑stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

1.2 If different erythropoiesis‑stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

  • National Institute for Health and Care Excellence (NICE)